Christopher Yuskaitis, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spasms, Infantile | 14 | 2023 | 305 | 3.280 |
Why?
|
| GTPase-Activating Proteins | 4 | 2022 | 497 | 1.830 |
Why?
|
| Glycogen Synthase Kinase 3 | 6 | 2010 | 430 | 0.880 |
Why?
|
| Seizures | 7 | 2023 | 2851 | 0.810 |
Why?
|
| Pentylenetetrazole | 1 | 2021 | 69 | 0.800 |
Why?
|
| Convulsants | 1 | 2021 | 70 | 0.790 |
Why?
|
| Fragile X Syndrome | 3 | 2010 | 115 | 0.740 |
Why?
|
| Epilepsy | 9 | 2023 | 3301 | 0.740 |
Why?
|
| Social Isolation | 1 | 2021 | 363 | 0.640 |
Why?
|
| Fragile X Mental Retardation Protein | 5 | 2013 | 117 | 0.630 |
Why?
|
| Fasting | 1 | 2022 | 1589 | 0.550 |
Why?
|
| Malformations of Cortical Development | 1 | 2017 | 200 | 0.520 |
Why?
|
| Anticonvulsants | 7 | 2022 | 1914 | 0.470 |
Why?
|
| Epilepsies, Partial | 1 | 2017 | 436 | 0.460 |
Why?
|
| Dyslexia | 1 | 2015 | 248 | 0.440 |
Why?
|
| Neurons | 4 | 2022 | 9325 | 0.440 |
Why?
|
| Vigabatrin | 3 | 2022 | 92 | 0.440 |
Why?
|
| Adrenocorticotropic Hormone | 3 | 2022 | 648 | 0.390 |
Why?
|
| Lithium Chloride | 2 | 2010 | 87 | 0.370 |
Why?
|
| Electroencephalography | 8 | 2022 | 6142 | 0.370 |
Why?
|
| Developmental Disabilities | 2 | 2018 | 1452 | 0.360 |
Why?
|
| Spasm | 4 | 2023 | 121 | 0.360 |
Why?
|
| Genetic Association Studies | 1 | 2019 | 2699 | 0.360 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2022 | 2107 | 0.350 |
Why?
|
| Disease Models, Animal | 6 | 2019 | 18006 | 0.340 |
Why?
|
| Avoidance Learning | 1 | 2010 | 233 | 0.320 |
Why?
|
| Astrocytes | 2 | 2017 | 1266 | 0.310 |
Why?
|
| Mice, Knockout | 8 | 2022 | 14554 | 0.280 |
Why?
|
| Child Development | 1 | 2018 | 2222 | 0.280 |
Why?
|
| Immune System | 1 | 2010 | 804 | 0.250 |
Why?
|
| Microglia | 2 | 2010 | 1261 | 0.230 |
Why?
|
| Prednisolone | 2 | 2021 | 333 | 0.220 |
Why?
|
| Infant | 14 | 2022 | 35070 | 0.200 |
Why?
|
| Mice, Inbred CBA | 1 | 2021 | 447 | 0.190 |
Why?
|
| Mice, 129 Strain | 1 | 2021 | 386 | 0.180 |
Why?
|
| Adaptor Protein Complex 4 | 1 | 2020 | 38 | 0.180 |
Why?
|
| Lissencephaly | 1 | 2020 | 38 | 0.180 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2022 | 2842 | 0.180 |
Why?
|
| Inflammation Mediators | 1 | 2008 | 1889 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase 5 | 1 | 2020 | 112 | 0.170 |
Why?
|
| Genes, Lethal | 1 | 2019 | 242 | 0.170 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2019 | 17400 | 0.170 |
Why?
|
| Spastic Paraplegia, Hereditary | 1 | 2020 | 157 | 0.160 |
Why?
|
| Brain | 7 | 2022 | 26343 | 0.160 |
Why?
|
| Sequence Analysis | 1 | 2018 | 256 | 0.150 |
Why?
|
| Mice | 10 | 2022 | 81045 | 0.150 |
Why?
|
| Congenital Abnormalities | 1 | 2022 | 707 | 0.150 |
Why?
|
| Gliosis | 1 | 2017 | 243 | 0.140 |
Why?
|
| Tuberous Sclerosis | 2 | 2022 | 1029 | 0.140 |
Why?
|
| Barbiturates | 1 | 2017 | 114 | 0.140 |
Why?
|
| Species Specificity | 1 | 2021 | 2479 | 0.140 |
Why?
|
| Hormones | 1 | 2021 | 884 | 0.140 |
Why?
|
| Carbamazepine | 1 | 2017 | 229 | 0.140 |
Why?
|
| Animals | 13 | 2022 | 168561 | 0.140 |
Why?
|
| Standard of Care | 1 | 2020 | 562 | 0.140 |
Why?
|
| Amino Acids | 1 | 2022 | 1727 | 0.140 |
Why?
|
| Neocortex | 1 | 2020 | 400 | 0.140 |
Why?
|
| Corpus Callosum | 1 | 2020 | 737 | 0.130 |
Why?
|
| Genetic Variation | 2 | 2022 | 6540 | 0.130 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2019 | 2505 | 0.130 |
Why?
|
| Pitch Perception | 1 | 2015 | 114 | 0.120 |
Why?
|
| Epilepsy, Benign Neonatal | 1 | 2013 | 16 | 0.120 |
Why?
|
| Cytoskeletal Proteins | 1 | 2020 | 1363 | 0.120 |
Why?
|
| Cell Movement | 3 | 2020 | 5212 | 0.120 |
Why?
|
| Outpatients | 1 | 2021 | 1483 | 0.120 |
Why?
|
| Coma | 1 | 2017 | 475 | 0.110 |
Why?
|
| Retrospective Studies | 11 | 2023 | 77098 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 3 | 2021 | 21821 | 0.110 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2013 | 154 | 0.110 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3130 | 0.100 |
Why?
|
| Music | 1 | 2015 | 259 | 0.100 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3236 | 0.100 |
Why?
|
| Sirolimus | 1 | 2019 | 1562 | 0.100 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2020 | 1581 | 0.100 |
Why?
|
| Cognition | 2 | 2022 | 6722 | 0.100 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2022 | 2906 | 0.100 |
Why?
|
| Child | 10 | 2023 | 77478 | 0.100 |
Why?
|
| Glucocorticoids | 1 | 2021 | 2107 | 0.100 |
Why?
|
| Age of Onset | 1 | 2018 | 3266 | 0.100 |
Why?
|
| Phenotype | 2 | 2019 | 16331 | 0.100 |
Why?
|
| Down Syndrome | 1 | 2019 | 880 | 0.090 |
Why?
|
| Speech | 1 | 2015 | 540 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2021 | 35342 | 0.090 |
Why?
|
| Male | 19 | 2023 | 349538 | 0.090 |
Why?
|
| Pandemics | 2 | 2020 | 8328 | 0.090 |
Why?
|
| Comprehension | 1 | 2015 | 608 | 0.090 |
Why?
|
| Lithium Carbonate | 1 | 2010 | 184 | 0.090 |
Why?
|
| Humans | 28 | 2023 | 742088 | 0.090 |
Why?
|
| Child, Preschool | 7 | 2020 | 40955 | 0.090 |
Why?
|
| Serine | 2 | 2010 | 828 | 0.090 |
Why?
|
| Genome, Human | 1 | 2022 | 4420 | 0.080 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2010 | 524 | 0.080 |
Why?
|
| Lithium | 2 | 2010 | 601 | 0.080 |
Why?
|
| Patient Readmission | 1 | 2023 | 3111 | 0.080 |
Why?
|
| Hippocampus | 1 | 2021 | 3661 | 0.080 |
Why?
|
| Female | 17 | 2023 | 379592 | 0.080 |
Why?
|
| Sex Factors | 1 | 2021 | 10392 | 0.070 |
Why?
|
| Repressor Proteins | 1 | 2018 | 3020 | 0.070 |
Why?
|
| Signal Transduction | 3 | 2019 | 23387 | 0.070 |
Why?
|
| Oximes | 1 | 2008 | 309 | 0.070 |
Why?
|
| Syndrome | 2 | 2023 | 3248 | 0.070 |
Why?
|
| Immunoblotting | 1 | 2010 | 1683 | 0.070 |
Why?
|
| Testis | 1 | 2010 | 800 | 0.070 |
Why?
|
| Benzazepines | 1 | 2008 | 326 | 0.070 |
Why?
|
| Nitric Oxide Synthase | 1 | 2008 | 916 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 8621 | 0.060 |
Why?
|
| Genotype | 1 | 2019 | 12946 | 0.060 |
Why?
|
| Age Factors | 1 | 2021 | 18355 | 0.060 |
Why?
|
| Indoles | 2 | 2008 | 1834 | 0.060 |
Why?
|
| Munc18 Proteins | 1 | 2022 | 29 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2022 | 62966 | 0.050 |
Why?
|
| Lipopolysaccharides | 1 | 2008 | 2211 | 0.050 |
Why?
|
| Cohort Studies | 5 | 2023 | 40450 | 0.050 |
Why?
|
| Autistic Disorder | 1 | 2010 | 1174 | 0.050 |
Why?
|
| Centrioles | 1 | 2020 | 79 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2008 | 2128 | 0.040 |
Why?
|
| Genetic Testing | 2 | 2022 | 3439 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2010 | 8436 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2008 | 3199 | 0.040 |
Why?
|
| Mutation | 3 | 2022 | 29717 | 0.040 |
Why?
|
| Pedigree | 2 | 2018 | 4646 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 890 | 0.040 |
Why?
|
| Videoconferencing | 1 | 2020 | 195 | 0.040 |
Why?
|
| Hemodiafiltration | 1 | 2017 | 20 | 0.040 |
Why?
|
| Prognosis | 1 | 2018 | 29010 | 0.040 |
Why?
|
| Brugada Syndrome | 1 | 2018 | 97 | 0.040 |
Why?
|
| INDEL Mutation | 1 | 2018 | 279 | 0.040 |
Why?
|
| Decontamination | 1 | 2017 | 69 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2006 | 1788 | 0.040 |
Why?
|
| Plasmapheresis | 1 | 2017 | 212 | 0.040 |
Why?
|
| Anxiety | 1 | 2010 | 4279 | 0.030 |
Why?
|
| Cytokines | 1 | 2010 | 7317 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2018 | 1589 | 0.030 |
Why?
|
| Microtubules | 1 | 2020 | 1090 | 0.030 |
Why?
|
| Health Resources | 1 | 2020 | 911 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2022 | 2502 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2021 | 10943 | 0.030 |
Why?
|
| Infant, Newborn | 3 | 2020 | 25575 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2008 | 19223 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 2938 | 0.030 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2013 | 171 | 0.030 |
Why?
|
| Neurology | 1 | 2020 | 762 | 0.030 |
Why?
|
| Multiprotein Complexes | 1 | 2018 | 1119 | 0.030 |
Why?
|
| Consanguinity | 1 | 2013 | 456 | 0.030 |
Why?
|
| Adolescent | 4 | 2022 | 85649 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2021 | 1952 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 24913 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2008 | 12071 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 1940 | 0.020 |
Why?
|
| Disease Management | 1 | 2020 | 2450 | 0.020 |
Why?
|
| Receptors, GABA-A | 1 | 2013 | 627 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2008 | 153 | 0.020 |
Why?
|
| Citrates | 1 | 2008 | 131 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2022 | 4282 | 0.020 |
Why?
|
| DNA | 1 | 2022 | 7289 | 0.020 |
Why?
|
| Maleimides | 1 | 2008 | 112 | 0.020 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2013 | 615 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 2013 | 2422 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 5385 | 0.020 |
Why?
|
| Probability | 1 | 2013 | 2502 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2017 | 1780 | 0.020 |
Why?
|
| Exploratory Behavior | 1 | 2008 | 270 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2020 | 4465 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 39004 | 0.020 |
Why?
|
| Inflammation | 1 | 2006 | 10578 | 0.020 |
Why?
|
| Urea | 1 | 2008 | 449 | 0.020 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2008 | 449 | 0.020 |
Why?
|
| Boston | 1 | 2019 | 9305 | 0.020 |
Why?
|
| Registries | 1 | 2020 | 8077 | 0.020 |
Why?
|
| Antimanic Agents | 1 | 2008 | 522 | 0.020 |
Why?
|
| Acoustic Stimulation | 1 | 2008 | 1216 | 0.020 |
Why?
|
| Choice Behavior | 1 | 2010 | 802 | 0.010 |
Why?
|
| Young Adult | 2 | 2020 | 56350 | 0.010 |
Why?
|
| Social Behavior | 1 | 2010 | 1128 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 7276 | 0.010 |
Why?
|
| Telemedicine | 1 | 2020 | 2853 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 5304 | 0.010 |
Why?
|
| Behavior, Animal | 1 | 2010 | 1882 | 0.010 |
Why?
|
| Mental Disorders | 2 | 2015 | 6587 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2006 | 1213 | 0.010 |
Why?
|
| Thiazoles | 1 | 2008 | 1484 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2008 | 6365 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2023 | 53187 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 3800 | 0.010 |
Why?
|
| Pyridines | 1 | 2008 | 2818 | 0.010 |
Why?
|
| United States | 1 | 2023 | 69693 | 0.010 |
Why?
|
| Adult | 2 | 2020 | 213712 | 0.010 |
Why?
|
| Risk Factors | 1 | 2020 | 72145 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2006 | 5724 | 0.000 |
Why?
|
| Middle Aged | 1 | 2020 | 213127 | 0.000 |
Why?
|
| Alzheimer Disease | 1 | 2006 | 7988 | 0.000 |
Why?
|
| Neoplasms | 1 | 2006 | 21596 | 0.000 |
Why?
|